Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13432MR)

This product GTTS-WQ13432MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13432MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7734MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ11475MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ15566MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ15958MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ4067MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ10689MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ2150MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ14501MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RYI-018
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW